When antitumor platinum drugs react with DNA they form various types of intrastrand and interstrand cross-links (CLs). One class of new antitumor platinum compounds comprises bifunctional Pt(II) compounds based on the dinuclear or trinuclear geometry of leaving ligands. It has been shown that the DNA-binding modes of dinuclear or trinuclear bifunctional Pt(II) agents are distinct from those of mononuclear cisplatin, forming markedly more intramolecular interstrand CLs. However, at least two types of DNA interstrand cross-linking by bifunctional Pt(II) complexes can be envisaged, depending on whether the platinum complex coordinates to the bases in one DNA molecule (intramolecular interstrand CLs) or in two different DNA duplexes (interduplex CLs). We hypothesized that at least some antitumor bifunctional poly(di/tri)nuclear complexes could fulfill the requirements placed on interduplex DNA cross-linkers. To test this hypothesis we studied the interduplex cross-linking capability of a representative of antitumor polynuclear agents, namely, dinuclear Pt(II) complex [{trans-PtCl(NH(3))(2)}(2)-μ-{trans-(H(2)N(CH(2))(6)NH(2)(CH(2))(2)NH(2)(CH(2))(6)NH(2))}](4+) (BBR3535). The investigations were conducted under molecular crowding conditions mimicking environmental conditions in the cellular nucleus, namely, in medium containing ethanol, which is a commonly used crowding agent. We found with the aid of native agarose gel electrophoresis that the DNA interduplex cross-linking efficiency of BBR3535 under molecular crowding conditions was remarkable: the frequency of these CLs was 54%. In contrast, the interduplex cross-linking efficiency of mononuclear cisplatin or transplatin was markedly lower (approximately 40-fold or 18-fold, respectively). We suggest that the production of interduplex CLs in addition to other DNA intramolecular adducts may provide polynuclear Pt(II) compounds with a wider spectrum of cytotoxicity.

Department of Biophysics Faculty of Sciences Palacky University 17 listopadu 12 77146 Olomouc Czech Republic

Zobrazit více v PubMed

Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1982-5 PubMed

Biochemistry. 1999 May 25;38(21):6781-90 PubMed

Biochim Biophys Acta. 1986 May 27;867(1-2):31-5 PubMed

Nucleic Acids Res. 1989 Dec 11;17(23):9719-33 PubMed

Nucleic Acids Res. 2009 Oct;37(19):6625-34 PubMed

Trends Biochem Sci. 2001 Oct;26(10):597-604 PubMed

J Inorg Biochem. 1999 Oct;77(1-2):43-6 PubMed

Cancer Res. 1983 Jun;43(6):2718-24 PubMed

Nat Rev Cancer. 2007 Aug;7(8):573-84 PubMed

Nat Rev Drug Discov. 2005 Apr;4(4):307-20 PubMed

J Med Chem. 1990 Aug;33(8):2179-84 PubMed

Biophysik. 1970;6(4):290-300 PubMed

J Mol Biol. 1974 Aug 25;87(4):817-33 PubMed

Biochimie. 2009 Mar;91(3):416-22 PubMed

Biochemistry. 1999 Aug 24;38(34):10997-1005 PubMed

J Am Chem Soc. 2009 Jul 8;131(26):9268-80 PubMed

Chem Res Toxicol. 2010 Nov 15;23(11):1833-42 PubMed

Nucleic Acids Res. 1996 May 1;24(9):1594-601 PubMed

Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5345-9 PubMed

Chem Commun (Camb). 2010 Sep 28;46(36):6640-50 PubMed

Chembiochem. 2007 Nov 5;8(16):2008-15 PubMed

Anticancer Drug Des. 1986 Apr;1(2):95-109 PubMed

Biopolymers. 1999 Dec;50(7):679-89 PubMed

Nature. 2003 Sep 4;425(6953):27-8 PubMed

Biochemistry. 1985 Jan 29;24(3):707-13 PubMed

Annu Rev Biophys Biomol Struct. 1993;22:27-65 PubMed

J Biol Chem. 2002 Dec 13;277(50):48076-86 PubMed

Biochemistry. 1992 Jan 28;31(3):842-9 PubMed

J Biol Inorg Chem. 2002 Apr;7(4-5):397-404 PubMed

Mutat Res. 1999 May 3;426(1):79-87 PubMed